Inmune Bio (INMB) Common Equity (2017 - 2025)
Inmune Bio (INMB) has disclosed Common Equity for 9 consecutive years, with $23.5 million as the latest value for Q4 2025.
- Quarterly Common Equity fell 26.71% to $23.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.5 million through Dec 2025, down 26.71% year-over-year, with the annual reading at $23.5 million for FY2025, 26.71% down from the prior year.
- Common Equity hit $23.5 million in Q4 2025 for Inmune Bio, down from $25.4 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $88.3 million in Q3 2021 to a low of $23.5 million in Q4 2025.
- Historically, Common Equity has averaged $48.7 million across 5 years, with a median of $43.6 million in 2021.
- Biggest five-year swings in Common Equity: soared 183.66% in 2021 and later plummeted 48.96% in 2024.
- Year by year, Common Equity stood at $80.2 million in 2021, then fell by 25.08% to $60.1 million in 2022, then tumbled by 37.87% to $37.3 million in 2023, then fell by 14.04% to $32.1 million in 2024, then dropped by 26.71% to $23.5 million in 2025.
- Business Quant data shows Common Equity for INMB at $23.5 million in Q4 2025, $25.4 million in Q3 2025, and $28.9 million in Q2 2025.